Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel
- 1 April 2008
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 48 (4), 475-484
- https://doi.org/10.1177/0091270008315310
Abstract
Prasugrel and clopidogrel, thienopyridine prodrugs, are each metabolized to an active metabolite that inhibits the platelet P2Y(12) ADP receptor. In this open-label, 4-period crossover study, the effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel were assessed in healthy subjects given single doses of prasugrel 60 mg and clopidogrel 300 mg with and without concurrent lansoprazole 30 mg qd. C(max) and AUC(0-tlast) of prasugrel's active metabolite, R-138727, and clopidogrel's inactive carboxylic acid metabolite, SR26334, were assessed. Inhibition of platelet aggregation (IPA) was measured by turbidimetric aggregometry 4 to 24 hours after each treatment. Lansoprazole (1) decreased R-138727 AUC(0-tlast) and C(max) by 13% and 29%, respectively, but did not affect IPA after the prasugrel dose, and (2) did not affect SR62334 exposure but tended to lower IPA after a clopidogrel dose. A retrospective tertile analysis showed in subjects with high IPA after a clopidogrel dose alone that lansoprazole decreased IPA, whereas IPA was unaffected in these same subjects after a prasugrel dose. The overall data suggest that a prasugrel dose adjustment is not likely warranted in an individual taking prasugrel with a proton pump inhibitor such as lansoprazole.Keywords
This publication has 14 references indexed in Scilit:
- The Disposition of Prasugrel, a Novel Thienopyridine, in HumansPublished by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2007
- Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics DifferentlyClinical Pharmacology & Therapeutics, 2007
- A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formationAmerican Heart Journal, 2007
- Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38)American Heart Journal, 2006
- REGULATION OF PLATELET FUNCTIONS BY P2 RECEPTORSAnnual Review of Pharmacology and Toxicology, 2006
- INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450Drug Metabolism and Disposition, 2006
- Atherothrombosis and High-Risk PlaqueJournal of the American College of Cardiology, 2005
- Pharmacology of CS-747 (prasugrel, LY640315), a Novel, Potent Antiplatelet Agent with in Vivo P2Y12Receptor Antagonist ActivitySeminars in Thrombosis and Hemostasis, 2005
- Platelets in atherothrombosisNature Medicine, 2002
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000